Immunization of melanoma patients with BEC2-keyhole limpet hemocyanin plus BCG intradermally followed by intravenous booster immunizations with BEC2 to induce anti-GD3 ganglioside antibodies

Clinical Cancer Research

Volumn 5, Issue 1, 1999, Pages 77-81

  Yao, Tzy Jyun ^a   Meyers, Michael ^a   Livingston, Philip O ^a   Houghton, Alan N ^a   Chapman, Paul B ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; ANTIIDIOTYPIC ANTIBODY; BCG VACCINE; GANGLIOSIDE ANTIBODY; GANGLIOSIDE GD3; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; KEYHOLE LIMPET HEMOCYANIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY BEC2; THERACYS; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY PRODUCTION; ARTICLE; CANCER IMMUNIZATION; CANCER REGRESSION; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUGATION; DRUG FORMULATION; FEMALE; HUMAN; IMMUNOGENICITY; INTRADERMAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MELANOMA; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; BCG VACCINE; CANCER VACCINES; DRUG ADMINISTRATION SCHEDULE; FEMALE; GANGLIOSIDES; HEMOCYANIN; HUMANS; IMMUNIZATION, SECONDARY; IMMUNOCONJUGATES; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRADERMAL; MALE; MELANOMA; MICE; MIDDLE AGED;

EID: 0032943590     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Nasi, M., Meyers, M., Livingston, P., Houghton, A., and Chapman, P. Anti-melanoma effects of R24, a monoclonal antibody against GD3. Vaccine Res., 7 (Suppl. 2): S155-S162, 1997.
2. Chapman, P. B., and Houghton, A. N. Induction of IgG antibodies against GD3 in rabbits by an anti-idiotypic monoclonal antibody. J. Clin. Invest., 88: 186-192, 1991.
3. McCaffery, M., Yao, T-J., Williams, L., Livingston, P. O., Houghton, A. N., and Chapman, P. B. Enhanced immunogenicity of BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside when combined with adjuvant. Clin. Cancer Res., 2: 679-686, 1996.
4. Chapman, P. B., McCaffery, M., Zuklys, K., Giorgio, N., and Houghton, A. N. Immunization with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: superiority of the intravenous route. Proc. Am. Assoc. Cancer. Res., 36: 493, 1995.
5. Mittelman, A., Chen, Z. J., Yang, H., Wong, G. Y., and Ferrone, S. Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma. Proc. Natl. Acad. Sci. USA, 89: 466-470, 1992.
6. Livingston, P. O. Approaches to augmenting the immunogenicity of melanoma gangliosides: from whole melanoma cells to ganglioside-KLH conjugate vaccines. Immunol. Rev., 145: 147-166, 1995.
7. Chapman, P. B., Livingston, P. O., Morrison, M. E., Williams, L., and Houghton, A. N. Immunization of melanoma patients with antiidiotypic monoclonal antibody BEC2 that mimics GD3 ganglioside: pilot trials using no immunological adjuvant. Vaccine Res., 3: 59-69, 1994.
8. Ritter, G., Boosfeld, E., Adluri, R., Calves, M., Oettgen, H. F., Old, L. J., and Livingston, P. O. Antibody response to immunization with ganglioside GD3 and GD3 congeners (lactones, amide and gangliosidol) in patients with malignant melanoma. Int. J. Cancer, 48: 379-385, 1991.
9. Grant, S. C., Yao, T-J., Kris, M. G., Rigas, J. R., Pisters, K. M. W., Miller, V., Houghton, A. N., and Chapman, P. B. Long survival following immunization with BEC2 plus BCG after initial therapy for small cell lung cancer. Proc. Am. Soc. Clin. Oncol., 15: 555, 1996.
10. Buzaid, A. C., Ross, M. I., Balch, C. M., Soong, S-j., McCarthy, W. H., Tinoco, L., Mansfield, P., Lee, J. E., Bedikian, A., Eton, O., Plager, C., Papadopolous, N., Legha, S. S., and Benjamin, R. S. Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. J. Clin. Oncol., 75: 1039-1051, 1997.
11. Stadelmann, W. K., Rapaport, D. P., Soong, S-J., Reinigen, D. S., Buzaid, A. C., and Balch, C. M. Predictive factors that influence melanoma outcome: prognostic clinical and pathologic features. In: C. M. Balch, A. N. Houghton, A. J. Sober, and S-J. Soong (eds.), Cutaneous Melanoma, Ed. 3, pp. 12-36. St. Louis, MO: Quality Medical Publishing, Inc., 1998.
12. Kirkwood, J. M., Strawderman, M. H., Ernstoff, M. S., Smith, T. J., Borden, E. C., and Blum, R. H. Interferon α-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J. Clin. Oncol., 14: 7-17, 1996.